Biofoundry-As-A-Service Market Report 2026

Biofoundry-As-A-Service Market Overview

• Biofoundry-As-A-Service market size has reached to $1.65 billion in 2025 • Expected to grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 21.6% • Growth Driver: Rising Investments In Life Sciences Are Driving The Market Growth Due To Expanding Capital For Biological Research • Market Trend: Advancements In Modular GMP Biofoundry Platforms Accelerate Biologics Development And Manufacturing Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biofoundry-As-A-Service Market?

Biofoundry-as-a-service is a model offering access to automated, high-throughput biological engineering facilities through remote or digital interfaces. It enables the design, construction, and testing of genetic constructs and organisms with minimal in-house infrastructure. Biofoundry-as-a-service accelerates synthetic biology workflows through integration of robotics, software, and data analytics into a streamlined platform. The main service types of biofoundry-as-a-service include design, build, test, learn, and integrated services. Design refers to the planning and engineering of biological systems using automated workflows and computational tools. They find application in pharmaceuticals, agriculture, industrial biotechnology, environmental, and other applications, serving end users including academic and research institutes, biotechnology companies, pharmaceutical companies, and other end users.

What Is The Biofoundry-As-A-Service Market Growth Forecast?

The biofoundry-as-a-service market size is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to growing deployment of AI-driven biofoundry platforms, increasing adoption of cloud-based design-build-test-learn services, rising demand for integrated bioengineering solutions, expansion of pharmaceutical and industrial biotechnology applications, increasing focus on scalable and high-throughput biofoundry operations. Major trends in the forecast period include increasing adoption of end-to-end dbtl cycle services, rising demand for automated dna assembly services, growing integration of machine learning modeling in biofoundries, expansion of platform-as-a-service bioengineering solutions, rising focus on high-throughput phenotypic and genotypic testing.

Global Biofoundry-As-A-Service Market Segmentation

1) By Service Type: Design, Build, Test, Learn, Integrated Services 2) By Application: Pharmaceuticals, Agriculture, Industrial Biotechnology, Environmental, Other Applications 3) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End Users Subsegments: 1) By Design: Pathway Design Services, Genetic Circuit Design Services, Strain Design And Optimization Services, Metabolic Engineering Design Services 2) By Build: Automated DNA Assembly Services, Strain Construction Services, Plasmid And Vector Construction Services, Synthetic Gene Synthesis Services 3) By Test: High-Throughput Screening Services, Phenotypic Characterization Services, Genotypic Validation Services, Assay Development And Testing Services 4) By Learn: Data Analysis And Interpretation Services, Machine Learning Modeling Services, Optimization And Feedback Services, Experimental Data Integration Services 5) By Integrated Services: End-to-End Biofoundry Services, Design-Build-Test-Learn (DBTL) Cycle Services, Custom Bioengineering Project Services, Platform-As-A-Service Integrated Solutions

What Is The Driver Of The Biofoundry-As-A-Service Market?

The rising investments in life sciences are expected to propel the growth of the biofoundry-as-a-service market going forward. Investments in life sciences refer to funding or allocating capital to companies, research, and technologies focused on healthcare, biotechnology, pharmaceuticals, medical devices, and related biological innovations. Investments in life sciences are growing due to rising demand for advanced healthcare solutions, as more people need innovative treatments, personalized medicine, and cutting-edge technologies to address complex diseases and improve overall health outcomes. Investments in life sciences drive the growth of biofoundry-as-a-service by providing the necessary capital to develop advanced automated platforms, accelerate high-throughput biological research, and enable scalable, customizable solutions for biotechnology companies and academic institutions. For instance, in September 2025, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, the UK government committed to allocating up to $707 million (£520 million) in capital grants to support inward investment in innovative life sciences manufacturing, reinforcing the country’s position as a leading hub for life sciences innovation. Therefore, the rising investments in life sciences are driving the growth of the biofoundry-as-a-service industry.

Key Players In The Global Biofoundry-As-A-Service Market

Major companies operating in the biofoundry-as-a-service market are GenScript Biotech Corporation, Ginkgo Bioworks Holdings Inc., Twist Bioscience Corporation, Codexis Inc., Emerald Cloud Lab Inc., Synbio Technologies LLC, Automata Technologies Limited, Telesis Bio Inc., Culture Biosciences Inc., Bioneer Corporation, Earlham Biofoundry Ltd., Arzeda Corporation, LabGenius Limited, Conagen Inc., Bota Biosciences Inc., Arctoris Ltd., Evonetix Ltd., Absci Corporation, TeselaGen Biotechnology Inc., SynbiCITE Innovation Hub.

Global Biofoundry-As-A-Service Market Trends and Insights

Major companies operating in the biofoundry-as-a-service market are focusing on deploying modular, automated biofoundry platforms to accelerate biologics development, streamline process optimization, and enhance scalable manufacturing capabilities. Modular, automated biofoundry platforms are advanced laboratory systems that integrate robotics, artificial intelligence–enabled software, and standardized biological processes to streamline the design, construction, testing, and optimization of biological systems with minimal manual input. For instance, in November 2024, Quotient Sciences, a UK-based drug development and manufacturing accelerator, installed Centillion’s GMP Biofoundry-in-a-Box platform to expand its integrated drug development and manufacturing services. The installation enhances the company’s ability to provide automated, high-throughput biologics development and GMP-compliant production, supporting clients with accelerated timelines, improved reproducibility, and scalable therapeutic manufacturing solutions.

What Are Latest Mergers And Acquisitions In The Biofoundry-As-A-Service Market?

In December 2023, Synplogen Inc., a Japan-based gene therapy solutions company, partnered with Ginkgo Bioworks Inc. to accelerate DNA manufacturing and gene therapy platform services in Japan. The partnership aims to expand access to high-quality DNA materials, streamline gene therapy development, and support innovative therapeutic programs for rare and complex diseases. Ginkgo Bioworks Inc. is a US-based biotechnology company that specializes in providing biofoundry-as-a-service (BFaaS).

Regional Insights

North America was the largest region in the biofoundry-as-a-service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biofoundry-As-A-Service Market?

The biofoundry-as-a-service market consists of revenues earned by entities by providing services such as protein expression and analysis, automated cell culture, metabolic pathway optimization, genome editing, enzyme engineering, pathway prototyping, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Biofoundry-As-A-Service Market Report 2026?

The biofoundry-as-a-service market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biofoundry-as-a-service industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.